ArticleJournal of rheumatic diseases2026
Diagnostic and monitoring value of serum interleukin-33 and rs16924159 polymorphism in relation to disease activity and tumor necrosis factor inhibitor response in rheumatoid arthritis.
Article in Journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to establish the diagnostic and monitoring value of serum interleukin-33 (IL-33) levels and IL-33 rs16924159 polymorphism regarding disease activity and response to tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients. Methods: In a case-control study, 100 RA patients and 100 healthy individuals were enrolled. We intentionally sampled 50 responders and 50 non-responders after 6 months of TNF inhibitors. Serum IL-33 levels were determined by using enzyme-linked immunosorbent assay (ELISA). Rs16924159 genotyping was performed using TaqMan real-time polymerase chain reaction. Disease activity was evaluated by the clinical disease activity index (CDAI), and treatment response was evaluated after 6 months of TNF inhibitor therapy. Results: IL-33 was markedly elevated in RA patients compared to controls (p<0.001), and IL-33 possessed satisfactory diagnostic accuracy area under the curve (AUC)=0.810 (95% confidence interval [CI]=0.747~0.872, p<0.001). Homozygous mutant AA genotype of rs16924159 was associated with higher disease activity (p<0.001) and poorer response to TNF inhibitors (odds ratio=5.26, 95% CI=1.07~25.77, p=0.040). Non-responders were found to have more elevated serum levels of IL-33 compared to responders (p<0.001). Serum IL-33 levels (p=0.015) and rs16924159 genotype (p<0.001) were significantly associated with CDAI scores. Conclusion: Elevated IL-33 and the rs16924159 polymorphism were associated with higher RA disease activity and lower 6 month TNF inhibitor response in this cohort. IL-33 showed moderate diagnostic performance (AUC=0.81, sensitivity=66%, specificity=92%), and routine clinical use-especially to guide personalized treatment-requires external validation in independent cohorts and prospective, comparative studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.